NLRP3 and metabolic dysfunction-associated steatohepatitis: Experimental studies showed that NASH (nonalcoholic steatohepatitis) induced by a high-fat diet is characterized by higher TLR4 expression and NLRP3 inflammasome activation, while the Gal-3 inhibitor reduced liver inflammation and TLR4, NLRP3, and caspase-1 expression levels [51].